Table 1 Characteristics of individual trials included in the meta-analysis
Author | Year | Country | Study type | Study design | Cases | Age (year) | Female (%) | Cancer (%) | Treatment | QMG | CMAP |
|---|---|---|---|---|---|---|---|---|---|---|---|
McEvoy | 1989 | USA | RCT | Cross-over | 12 | 34–75 | 8(66.7 %) | 7(58.3 %) | 3,4-DAP | N/A | CMAP |
Sanders | 2000 | USA | RCT | Parallel | 26 | 41–68 | 15(57.7 %) | 10(38.5 %) | 3,4-DAP | QMG | CMAP |
Oh | 2009 | USA | RCT | Cross-over | 6 | 25–75 | 1(16.7) | 2(33.3 %) | 3,4-DAP | QMG | CMAP |
Wirtz | 2009 | Netherlands | RCT | Cross-over | 9 | 33–73 | 4(44.4 %) | N/A | 3,4-DAP | N/A | CMAP |
Oh | 2016 | USA | RCT | Parallel | 36 | 21–88 | 23(63.9 %) | 6(16.7 %) | 3,4-DAP | QMG | CMAP |
Shieh | 2019 | USA | RCT | Parallel | 26 | 31–75 | 16(61.5 %) | 6(23.1 %) | 3,4-DAP | QMG | N/A |